Leukemia treatment gets rushed approval

WASHINGTON (AP) -- A Bristol-Myers Squibb Co. drug received accelerated federal approval Wednesday to treat some leukemias where other drugs have failed.
The drug dasatinib, being sold under the brand-name Sprycel, won Food and Drug Administration approval to treat all phases of chronic myeloid leukemia in patients with either resistance or intolerance to the drug Gleevec.